Abivax (ABVX) Operating Expenses (2022 - 2026)

Abivax (ABVX) has reported Operating Expenses for 5 consecutive years, with -$67.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses fell 32.96% year-over-year to -$67.4 million; the TTM figure through Mar 2026 stood at $281.5 million (up 44.68% YoY), while the FY2025 annual figure was $291.7 million, up 47.23% from the prior year.
• Operating Expenses came in at -$67.4 million for Q1 2026 at Abivax, down from $499.6 million in the prior quarter.
• The five-year high for Operating Expenses was $499.6 million in Q4 2025, with the low at -$96.7 million in Q3 2025.
• Average Operating Expenses over 5 years is $38.8 million, with a median of -$49.8 million recorded in 2024.
• Across the five-year window, Operating Expenses tumbled 137.38% in 2023 and soared 256009642.09% in 2024, its largest moves.
• Year by year, Operating Expenses stood at -$56.93 in 2022, then sank by 137.38% to -$135.14 in 2023, then soared by 256009642.09% to $346.0 million in 2024, then surged by 44.4% to $499.6 million in 2025, then sank by 113.49% to -$67.4 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered -$67.4 million, $499.6 million, and -$96.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.